一種記錄和監(jiān)測(cè)腦部電活動(dòng)新型神經(jīng)監(jiān)測(cè)系統(tǒng)被設(shè)計(jì)用于急性監(jiān)護(hù)患者：例如嚴(yán)重癲癇接受選擇性外科手術(shù)治療的患者，腦卒中和腦損傷接受顱骨切開(kāi)手術(shù)的患者。這套系統(tǒng)已經(jīng)獲得了美國(guó)食品藥品管理局的許可。

這套系統(tǒng)包括NeuroPort腦皮質(zhì)層微電極檢測(cè)（NeuroPort檢測(cè)）以及NeuroPort神經(jīng)信號(hào)處理器（NeuroPort NSP）。NeuroPort系統(tǒng)為神經(jīng)科醫(yī)生和神經(jīng)外科醫(yī)生提供了一種檢測(cè)、傳播以及分析接受顱骨切開(kāi)手術(shù)患者的神經(jīng)活動(dòng)的新方法。這種檢測(cè)方法可以從大腦皮質(zhì)層收集綜合的或者單個(gè)的神經(jīng)信號(hào)。NSP可以記錄這些信號(hào)，醫(yī)生通過(guò)分析這些信號(hào)，將其做為診斷與治療神經(jīng)系統(tǒng)疾病的一部分。

研制開(kāi)發(fā)這套系統(tǒng)的Cyberkinetics神經(jīng)技術(shù)系統(tǒng)公司的總裁兼首席執(zhí)行官Timothy R.Surgenor說(shuō)：“NeuroPort系統(tǒng)是我們首個(gè)商業(yè)化的臨床產(chǎn)品，其獲得上市許可，是我們公司開(kāi)發(fā)用于診斷、檢測(cè)和治療神經(jīng)系統(tǒng)疾病和損傷產(chǎn)品戰(zhàn)略極其重要的第一步。NeuroPort檢測(cè)和NeuroPort SNP是來(lái)自我們BrainGate神經(jīng)界面系統(tǒng)的重要組成部分。”
 
Neural Monitoring of Acute Care Patients
 
A new neural system that records and monitors brain electrical activity is designed for patients in acute care, such as patients undergoing elective surgery for the treatment of severe epilepsy and patients undergoing emergency craniotomies for stroke and brain injury. The system has been cleared by the U.S. Food and Drug Administration (FDA).

The system comprises the NeuroPort cortical microelectrode array (NeuroPort array) and the NeuroPort neural signal processor (NeuroPort NSP). The NeuroPort system provides neurologists and neurosurgeons with a new resource to detect, transmit, and analyze neural activity of patients who have undergone craniotomy. The array allows the collection of aggregate or individual neural signals from the cortical region of the brain. The NSP allows these signals to be recorded and analyzed by the doctor as a part of the diagnosis and treatment of neurologic conditions.

“Marketing clearance of the NeuroPort system, our first commercial clinical product, is an important first step in our strategy to develop a broad family of products to diagnose, monitor, and treat neurological diseases and injuries,” noted Timothy R. Surgenor, president and CEO of Cyberkinetics Neurotechnology Systems, Inc. (Foxborough, MA, USA), which developed the system. “The NeuroPort array and the NeuroPort SNP are both critical components derived from our BrainGate neural interface system.”